Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Camzyos
Biotech
Braveheart pays $65M to challenge BMS for heart disease market
Braveheart has waded into the fight for a heart disease market, paying $65 million upfront for a rival to BMS’ Camzyos and Cytokinetics’ aficamten.
Nick Paul Taylor
Sep 5, 2025 9:05am
FDA pushes back Cytokinetics' heart drug PDUFA to year-end
May 2, 2025 7:48am
Sanofi scoops up China rights to Cytokinetics' heart disease med
Dec 20, 2024 11:07am
Edgewise unveils promising early data for heart disease drug
Sep 20, 2024 4:00am
Cytokinetics shows hand in high stakes rivalry with BMS' Camzyos
May 13, 2024 9:36am
